Replies to post #206058 on Biotech Values

[DewDiligence]

RETA cancels public offering due to “adverse market conditions”:

http://finance.yahoo.com/news/reata-pharmaceuticals-inc-announces-requested-120000969.html

[DewDiligence]

RETA starts phase-2/3 trial in Alport syndrome:

http://finance.yahoo.com/news/reata-announces-initiation-phase-2-141500386.html

Reata expects data from the Phase 2 portion of the trial to be available, and to decide on entering the Phase 3 portion, by year-end 2017.

‘poorgradstudent’ is bearish on this program and on the drug candidate, bardoxolone in general.